Chapter 6 of 25
- Read the exact HPV and cytology result
- Combine with prior history
- Repeat testing or colposcopy as indicated
- Treat and monitor significant precancer
What you will learn
Decode cytology and biopsy terms; understand risk-based follow-up; distinguish repeat testing from colposcopy or treatment.
Cell-test terms in plain language
| Result | Meaning |
|---|---|
| ASC-US | Squamous cells look slightly unusual; the cause is uncertain |
| LSIL | Low-grade squamous changes, often associated with HPV |
| HSIL | High-grade squamous changes with greater concern for significant precancer |
| ASC-H | A high-grade squamous lesion cannot be excluded |
| AGC | Atypical glandular cells; assessment may include the cervical canal and, in selected people, the uterine lining |
These terms describe a screening sample. They do not by themselves establish how far disease extends. HPV-positive means the assay detected a targeted high-risk type; HPV-negative lowers risk but does not explain symptoms or cancel every prior abnormality. An inadequate sample may need repeating because it cannot be interpreted reliably.
Biopsy terms are different
CIN1 describes low-grade squamous changes in tissue, often monitored because regression is common. CIN2 and CIN3 are high-grade precancers. Selected CIN2 can be observed under a strict protocol when fertility concerns, age and adequate assessment support that choice. CIN3 generally needs treatment outside pregnancy-specific circumstances. AIS is glandular precancer and often needs diagnostic excision to exclude hidden invasion and evaluate margins.
A biopsy can sometimes find less or more severe disease than cytology suggested. The clinician reconciles the results, HPV type, examination and whether the transformation zone was completely seen. Unexpected disagreement can require pathology review or another sample rather than assuming one result is irrelevant.
Why follow-up is based on risk
Risk-based management combines the current test with age, prior HPV and cytology results, previous biopsy or treatment, and special circumstances. The same ASC-US result may lead to different next steps in two people. Some low-risk combinations can be retested after a defined interval; high-grade findings, certain HPV results or persistent abnormalities commonly prompt colposcopy.
Colposcopy uses magnification to guide small biopsies. It is an examination, not a cancer treatment. In selected high-risk situations a clinician may discuss an excisional treatment without a preceding separate biopsy, but this requires careful shared decision-making and does not apply to every positive HPV result. Pregnancy, young age and fertility priorities can substantially change that discussion.
Making the plan understandable
Ask the clinic to write down the test name, result, recommended action and deadline. Confirm how you will receive biopsy results and whom to contact if no message arrives. “Repeat later” should mean a specific date, not an indefinite delay. Bring earlier results because the trend may change the recommendation.
If you are pregnant, disclose this before endocervical sampling or treatment. Some diagnostic procedures are appropriate during pregnancy, while endocervical curettage is avoided. Suspected invasion needs specialist assessment; routine treatment of precancer is usually deferred with a safe surveillance plan.
Misconception and common question
“HSIL means advanced cancer” is false: it is a high-grade screening finding requiring timely evaluation. Can I simply retest a high-grade result until it becomes normal? No. Follow the recommended assessment because repeat screening alone can miss important disease.
Take-home messages
Read the exact report, not just “positive.” Keep follow-up dates and previous records. A reliable pathway prevents both unnecessary treatment and dangerous delay.
References and review status
- NCI — HPV and Pap test results: next steps
- ASCCP — Risk-based management consensus guidelines and resources
- WHO — Screening and treatment recommendations, 2021
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy